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Objectives: In order to investigate real-world values data; blood pressure, LDL-c, 
and HbA1c, in Japan from various perspectives and to assess the degree to which 
health condition in Japan is reflected in database, we conducted a comparative 
assessment using three databases: Minacare database, a large database containing 
health care checkup results from employment-based health insurance recently 
developed, and the publicly available two nation-wide databases. MethOds: A 
retrospective, cross sectional study using the Japanese health care checkup data-
base developed by MinaCare Co. Ltd. was designed to investigate the distribution 
of the real-world values of BP, LDL-c, and HbA1c in Japan. The data were compared 
to those in Specific Health Checkups and Specific Health Guidance (MHLW-SH) and 
National Health and Nutrition Survey (MHLW-H&N). Results: There were 232,515 
subjects with health care checkup results in 2011 MinaCare database. The propor-
tion of subjects with SBP≥ 140 mmHg, LDL-c≥ 140 mg/dL, and HbA1c≥ 6.1% generally 
increase with age; in the 55-60 year age range, the proportions were 19.0% (males) 
and 12.2% (females) for SBP, 27.2% and 42.7% for LDL-c, and 13.5% and 5.4% for 
HbA1c, respectively. The MinaCare database was mostly comparable to MHLW-SH 
and MHLW-H&N databases. However, some notable differences were seen for MHLW-
H&N compared to MinaCare and MHLW-SH in the values of BP and lipid param-
eters. cOnclusiOns: Analysis of MinaCare database indicated that substantial 
proportions of subjects have BP, LDL and HbA1c levels that are not well controlled 
in accordance with the Japanese guidelines. The results were generally consistent to 
the national databases. In light of the characteristics of MinaCare database such as 
the low selection bias, large sample size, wide age distribution, and high flexibility 
in the analysis of subject-level data, the database is highly valuable in studying the 
health status of the population insured by the employment-based health insurance.
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Objectives: The American College of Chest Physicians, the European Society 
of Cardiology guidelines, and published decision support tools by LaHaye and 
Casciano offer recommendations to guide oral anticoagulant (OAC) treatment in 
patients with atrial fibrillation (AF). The aim of our study is to compare the predic-
tive validity of these aids by contrasting the net clinical benefit when OAC use is 
concordant/discordant with each of the aids. MethOds: A cohort study using the 
2006-2013 Lifelink claims data was used to compare the net clinical benefit (NCB) 
of AF patients. NCB is the difference in event rates of composite events (thrombo-
embolic stroke and major bleed events per 10,000 person years) between patients 
who are concordant and those who are discordant with the guideline/tool recom-
mendations. Cox proportional hazard models were used to assess the relative risk 
of composite thromboembolic and bleed events adjusted for potential confound-
ers. Results: A total of 11,315 AF patients contributing 27,801 person years met 
the study inclusion criteria. The NCB of patients concordant with recommendations 
of the LaHaye tool (34.81[C.I= 33.4-36.23]) was highest followed by American guide-
lines (22.75[C.I= 21.40-24.17]), Casciano tool (16.99[C.I= 15.57-18.40]) and European 
guidelines (3.94[C.I= 2.52-5.35]). By restricting the definition of composite events to 
ischemic stroke and intracranial hemorrhage; the NCB of patients concordant with 
American guidelines (24.20[C.I= 22.88-25.52]) was highest followed by Casciano tool 
(17.07[C.I= 15.75-18.38]), LaHaye tool (14.30[C.I= 12.99-15.62]) and European guide-
lines (11.25[C.I= 9.93-12.57]). There was no significant decrease in the risk of com-
posite events associated with concordant OAC use/non-use for any of the decision 
aids after multivariate adjustment. cOnclusiOns: These results suggest that OAC 
use/non-use consistent with any of the tools led to net clinical benefits but the rank 
order depended on the composite outcomes selected. However, the benefit vanished 
after multivariate adjustment. Larger studies are warranted before any one OAC 
decision aid can be recommended to routinely guide OAC treatment decisions.
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Objectives: Published atrial fibrillation (AF) guidelines and decision tools offer 
oral anticoagulant (OAC) recommendations however they consider stroke and 
bleed risk differently. The aims of our study are to (i)empirically compare the treat-
ment recommendations by the American College of Chest Physicians guidelines, 
the European Society of Cardiology guidelines, and two published decision tools 
published by Casciano and LaHaye and (ii) to compare the concordance of OAC 
use with their recommendations. MethOds: A cross sectional study using the 
2006-2013 Lifelink claims data was used to contrast the treatment recommenda-
tions of these AF-OAC decision aids. CHADS2VASc and HAS-BLED algorithms were 
used to stratify 11,315 AF subjects into 9 stroke and bleed risk groups to study the 
variation in treatment recommendations. The concordance of actual OAC use with 
each of the decision aid’s treatment recommendations was compared. Results: 
The European guidelines recommended OAC most often (84.96%) and a conserva-
tive LaHaye tool recommended warfarin OAC the least often (13.41%). None of the 
decision aids recommended OAC for subjects with low stroke risk (CHADS2VASc= 0). 
However, OAC treatment recommendations varied considerably when stroke risk 
was moderate or high (CHADS2VASc> 0). For example, the LaHaye tool never recom-
mended warfarin OAC for persons with CHADS2VASc= 1 irrespective of bleed risk, 
however, the European guidelines preferred OAC for persons with CHADS2VASc= 1 
and a HAS-BLED< 3. Actual OAC use was most consistent with the Casciano tool 
(49.43%) and was least consistent with the LaHaye tool (44.52%). cOnclusiOns: 
OAC prescribing could be improved as actual OAC use/non-use was often discordant 
with all the recommendations. There is considerable variability in OAC treatment 
recommendations by the AF guidelines and decision tools when ischemic stroke risk 
is moderate or high. Empirical evidence is needed to compare the outcomes of OAC 
treatment recommendations by each of these decision aids before implementing 
one of these to inform clinical decisions.
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Objectives: Pharmaceutical companies utilize various promotional strategies to 
advertise a drug during its patent life. Study purpose was to understand these strate-
gies by exploring the content of drug advertising using the framework of Product 
Life Cycle (PLC). During different stages of PLC, this study assessed drug ads for 
the following: (1) type of characters appearing in the ad, (2) source of information 
(SOI) for the drug, and (3) ad appeals (rational vs. emotional). MethOds: Unique 
ads of Pfizer, Inc. drug Lipitor (Atorvastatin), aired during CNN evening news (from 
Jan 1st ’96 – Nov 30th ’11 [patent life of Lipitor]), were evaluated. The Vanderbilt TV 
News Archive provided the advertising content. PLC phases were defined as fol-
lows: introduction and growth (Phase-I: 1999-2002); maturity (Phase-II: 2003-2006); 
and decline (Phase-III: 2007-2011). Code sheet was developed using prior literature 
and pilot-tested for the final study. Four coders were trained in coding procedures. 
Reliability was measured with Cohen’s kappa. Data were analyzed using descrip-
tive statistics and cross-tabulations. Results: Twenty-one (phase-I: 2; phase-II: 7; 
phase-III: 12) unique product-specific ads were analyzed. Researchers of the adver-
tised drug appeared more in phase-II [3 (43%) of 7 vs. 3 (25%) of 12 in phase-III)]. 
Person with medical condition appeared more in phase-III [9 (75%) of 12 vs 4 (57%) of 
7 in phase-II)]. In all three phases an anonymous voice provided drug information. 
Researchers were a SOI in phase-II [3 (43%) of 7 ads] and a person with medical con-
dition was a SOI in phase-III [7 (58%) of 12]. The appeal of phase-II ads was rational 
compared to ads in phase-III [4 (57%) of 7 vs. 5 (43%) of 12 ads]. cOnclusiOns: 
Distinctive ad strategies were observed throughout the PLC of Lipitor. These dif-
ferentiated strategies coincided with shifts in PLC phases, which indicate a change 
in ads based on the phase of PLC.
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Objectives: To evaluate the medical quality of a Central Illinois health care 
system by developing a predictive model to identify those patients who might 
be more likely to be readmitted with 30 days of discharge based upon their fac-
tors, determinants and demographic/clinical characteristics. MethOds: This is 
a retrospective study integrating the information compiled in a Central Illinois 
hospital administrative database from 2010 to 2013 of patients admitted with 
acute myocardial infarction (AMI), Heart Failure (HF) or Pneumonia, capturing 
data including readmissions within 30 days, diagnosis, treatment, gender, age, 
education, race, medical insurance, health care provider, specific comorbidities 
etc… A multivariable generalized linear model and Bayesian analysis were used to 
predict adjusted hospital readmission rates including all-cause, AMI, HF and pneu-
monia. Results: The average adult readmission rates were 15.2% (1554/10244) 
for all-cause, 8.9% (272/3058) for AMI, 15.6% (583/3740) for pneumonia and 20.3% 
(699/3446) for HF. Among adults higher readmission rates were significantly more 
likely to occur among Black Americans (21.2% of all readmissions), those who have 
separated, divorced or widowed (17% of all readmissions), elderly with AMI, those 
individuals living in metropolitan areas (16.6% of all readmissions), underweight 
individuals (26% of all readmissions), and those individuals with longer length 
of stay and comorbidities. The HF and AMI specific admission data were utilized 
to develop and test the predictive model. The sensitivity and specificity were 
56.1% and 57.6% for HF and 67.9% and 66.6% for AMI, respectively. cOnclusiOns: 
Predictive modeling can serve to identify patients who could be more likely to be 
readmitted. More information is required to improve the accuracy of the model. 
The model could be operationalized in a hospital setting to identify high-risk 
individuals who may benefit from interventions upon discharge.
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Objectives: In 2011, the US Centers for Medicare and Medicaid Services (CMS) 
established the Hospital Value-Based Purchasing (HVBP) program in which hospitals 
were assigned quality scores related to their treatment of inpatients. The primary 
objective of this study was to measure, among acute myocardial infarction (AMI) 
and heart failure (HF) inpatients, the association between hospital quality of care 
scores and the difference between hospital charges and reimbursement amounts 
(the Delta). This research has potential implications related to inpatient procedure 
quality measures and hospital charging behavior. MethOds: The Delta between 
hospital charges and reimbursement was calculated for patients with an AMI or HF 
from 2011 Medicare inpatient claims. Quality was assessed with CMS’s 2011 Hospital 
Compare AMI and HF quality component scores. To measure the adjusted associa-
tion between the Delta and quality scores, generalized linear mixed models were fit 
separately for AMI patients and HF patients. The models controlled for both patient 
and hospital characteristics. Results: The AMI model was fit using 110,076 claims 
across 1,383 hospitals. After controlling for patient and hospital factors, each 1-point 
increase in AMI quality score yielded a 0.5% increase in Delta (p-value = 0.01). The 
HF model was fit using 468,974 claims across 2,813 hospitals. The adjusted HF model 
revealed that a point increase in HF quality score yielded a 1.0% increase in Delta 
